Companies › IGC Pharma
1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IGC-AD1 Delta-9-tetrahydrocannabinol (THC) | CNR1, CNR2 | Phase 2 | Alzheimer Disease | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05543681 | IGC-AD1 | Phase 2 | Alzheimer Disease | Neurology | Nov 2026 |
Cash and short-term investments of $0m on 2026-09-30; operating cash outflow about $5m a year; runway about 1 months at that burn, to Oct 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Zynerba Pharmaceuticals Bazelet Nehushtan Incannex Healthcare Vertanical Alasht Pharmed Jazz Pharmaceuticals Sinfatin Skye Bioscience PleoPharma Laboratorio Elea Phoenix
NeuroTherapia Larimar Therapeutics Satellos Bioscience Coya Therapeutics PepGen
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.